Abstract:You have accessJournal of UrologyProstate Cancer: Basic Research & Pathophysiology II1 Apr 2018MP64-10 INFILTRATING CD4+ T CELLS ATTENUATED THE SENSITIVITY OF CHEMOTHERAPY IN PROSTATE CANCER VIA SECRETING CCL5 Peng Xiang, Shuai Hu, Song Jin, Yang Yang, JingDong Sheng, and Jie Jin Peng XiangPeng Xiang More articles by this author , Shuai HuShuai Hu More articles by this author , Song JinSong Jin More articles by this author , Yang YangYang Yang More articles by this author , JingDong ShengJingDong Sheng More articles by this author , and Jie JinJie Jin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2055AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Management of castration-resistant prostate cancer (CPRC) remains challenging because of the unavoidable emergence of acquired resistance to chemotherapy with docetaxel(Doc). The tumor immune micro-environment as well as their secreted cytokines and growth factors play a substantial role in tumor survival and development of resistance to chemotherapy. Our early study have proved that CD4(+)T cells in prostate tumor micro-environment contribute to prostate cancer(PCa) progression, however, their effects on PCa chemo-sensitivity remained unclear. METHODS CD4+T cell infiltration from post-chemotherapy paraffin embedded specimens was performed by IHC. CRPC cell lines--C4-2, CWR22RV1 and CD4(+) T cell lines--HH and Molt-3 were used in vitro co-culture system. After 48 hours co-culture, the PCa cell chemo-sensitivity were detected by CCK8, Tunel and Western-blot. Various cell cytokine was determined by Cytokine arrays and QPCR. RESULTS We found more CD4+T cell infiltration in tumor area (Figure 1A) than in adjacent normal prostate (Figure 1B) in clinical samples. After co-culture with the CD4+T cells, C4-2 and 22Rv1 cells become more resistant to Doc treatment in a dose-dependent manner ranging from 1 nM to 8 nM (Figure 2A). Tunel results indicated that CD4+T cells protect PCa cells from Doc-induced apoptosis (Figure 2C). Meanwhile, the level of cleaved PARP, another indicator for the apoptotic process were also decreased (Figure 2B). QPCR and Cytokine arrays indicates that after co-culture with PCa CD4+T cells could secrete a significantly higher CCL5 (Figure 3A). Moreover, CCL5 stimulation enhanced PCa resistance to docetaxel(Figure 3B). Anti-ccl5 neutralization antibody could reverse co-culture PCa resistance to docetaxel. CONCLUSIONS CD4+T cells significantly attenuated prostate cancer chemo-sensitivity in vitro. Additionally, CCL5 secreted by CD4+T cells plays a key factor in chemo-therapy resistance. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e853-e854 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Peng Xiang More articles by this author Shuai Hu More articles by this author Song Jin More articles by this author Yang Yang More articles by this author JingDong Sheng More articles by this author Jie Jin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Effect of Tumor CD276 Expression on Infiltrating Immune Cells and Clinicopathological Features of Prostate Cancer

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

Immune Response Drives Outcomes in Prostate Cancer: Implications for Immunotherapy

A Double-Edged Sword Role of Cytokines in Prostate Cancer Immunotherapy

Prevalence of Tumour-Infiltrating CD103+ Cells Identifies Therapeutic-Sensitive Prostate Cancer with Poor Clinical Outcome

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

A Pan-Cancer Analysis of the Oncogenic Role of CD276 in Human Tumors

Protocadherin-1 Serves As a Prognostic Biomarker and Promotes Pancreatic Cancer Progression by Suppressing CD8+ T Cell Infiltration Through CCL5-CCR5 Axis.

Infiltrating CD4+ T cells attenuate chemotherapy sensitivity in prostate cancer via CCL5 signaling

Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy

Tumor ABCC4-mediated release of PGE2 induces CD8+ T cell dysfunction and impairs PD-1 blockade in prostate cancer

Abstract B22: B7-H3 promotes progression of prostate cancer harboring PTEN and TP53 defects

Upregulation of TIM3 and reduced expression of PD-1 on immune cell subsets in advanced prostate cancers

Identification and Validation of a Poor Clinical Outcome Subtype of Primary Prostate Cancer with Midkine Abundance

MP64-10 INFILTRATING CD4+ T CELLS ATTENUATED THE SENSITIVITY OF CHEMOTHERAPY IN PROSTATE CANCER VIA SECRETING CCL5

The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target

The Immune Microenvironment in Prostate Cancer: A Comprehensive Review

Immune signature driven by ADT-induced immune microenvironment remodeling in prostate cancer is correlated with recurrence-free survival and immune infiltration

Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma